Andere Sprachen Pyxis Oncology, Inc.

Aktien

A3C45M

US7473241013

PYXS

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:53:00 01.05.2024			% 5 Tage	% 1. Jan.
4,525 ^USD	+1,69 %		-1,46 %	+143,61 %

22.03.	PYXIS ONCOLOGY, INC. : HC Wainwright behält die Bewertung Kaufen bei	ZM
21.03.	Pyxis Oncology, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pyxis Oncology : Stifel 2024 Virtual Targeted Oncology Forum	17.04.
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	28.03.
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights	27.03.
Health Care Up on Drug Sales Optimism -- Health Care Roundup	21.03.
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023	21.03.
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA	13.03.
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA	13.03.
Pyxis Oncology, Inc. Appoints Santhosh Palani to Its Board of Directors	13.03.
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024	07.03.
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting	05.03.
Pyxis Oncology Announces Private Placement of Shares, Pre-Funded Warrants to Raise $50 Million	27.02.
Pyxis Oncology Announces $50 Million Private Placement	27.02.
Pyxis Oncology Announces $50 Million Private Placement	27.02.
Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investors	26.02.
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29.12.
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29.12.
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer	28.11.
Pyxis Oncology, Inc. Appoints Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer	28.11.
Pyxis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Pyxis Oncology, Inc.

Aktien

A3C45M

US7473241013

PYXS

Andere Sprachen

Filter